AVTX · Avalo Therapeutics, Inc.
Market Cap
$1.05B
Shares
53.63M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-08-06 | — | |
| 8-K | 2026-06-23 | — | |
| 8-K | 2026-06-16 | — | |
| 8-K | 2026-06-12 | 2026-06-11 | |
| 8-K | 2026-06-08 | 2026-06-02 | |
| 10-Q | 2026-05-13 | 2026-03-31 | |
| 8-K | 2026-05-13 | — | |
| 8-K | 2026-05-07 | 2026-05-05 | |
| 8-K | 2026-05-05 | — | |
| 8-K | 2026-04-28 | 2026-04-26 | |
| DEF 14A | 2026-04-10 | — | |
| 8-K | 2026-03-27 | 2026-03-23 | |
| 10-K | 2026-03-23 | 2025-12-31 | |
| 8-K | 2026-03-23 | — | |
| 8-K | 2026-01-12 | — | |
| 8-K | 2025-12-02 | — | |
| 10-Q | 2025-11-06 | 2025-09-30 | |
| 8-K | 2025-11-06 | — | |
| 8-K | 2025-10-29 | — | |
| 8-K | 2025-10-10 | — | |
| 8-K | 2025-10-01 | 2025-09-29 | |
| 8-K | 2025-09-22 | 2025-09-16 | |
| 8-K | 2025-08-07 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-06-20 | — | |
| 8-K | 2025-06-18 | 2025-06-17 | |
| 8-K | 2025-06-17 | — | |
| 8-K | 2025-06-05 | 2025-06-03 | |
| 8-K | 2025-06-04 | — | |
| 10-Q | 2025-05-12 | 2025-03-31 | |
| 8-K | 2025-05-12 | — | |
| 8-K | 2025-05-08 | — | |
| DEF 14A | 2025-05-01 | 2025-06-17 | |
| 8-K | 2025-03-26 | 2025-03-25 | |
| 8-K | 2025-03-20 | — | |
| 10-K | 2025-03-20 | 2024-12-31 | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2025-01-02 | 2025-01-01 | |
| 8-K | 2024-12-05 | — | |
| 8-K | 2024-11-12 | — | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-11-07 | — | |
| 8-K | 2024-10-08 | — | |
| 8-K | 2024-09-09 | — | |
| 8-K | 2024-09-04 | 2024-09-03 | |
| 8-K | 2024-08-14 | 2024-08-13 | |
| 8-K | 2024-08-12 | — | |
| 10-Q | 2024-08-12 | 2024-06-30 | |
| 8-K | 2024-07-30 | 2024-07-29 |
Showing 1–50 of 168 filings
Key facts
CIK
1534120
CUSIP
05338F306
13F (30d)
127 filings
118 filers
Visit website
Investor relations